One inhaler, three medicines: a world's-first for 55 million lungs

For the more than 55 million Indians living with COPD — a lung disease that slowly steals the breath — treatment often means juggling several inhalers, each with its own technique and timing. Lupin's Formoflo-G, launched in India this week after the national drug regulator's approval, folds three established medicines into a single twice-daily puff: the first fixed-dose triple-combination inhaler of its kind anywhere in the world. Fewer devices, fewer missed doses, easier breathing — for a condition that remains one of India's leading causes of death and disability.